CEBINA is led by a team of highly experienced academic and medical research scientists and entrepreneurs with decades-long experience in product development and biotech innovation
Management Team
Eszter Nagy, MD, PhD
CEO, CSO Founder
Over 20 years of biotech experience and serial entrepreneurship, successfully raising >€40M VC financing and €16M non-dilutive funding
Co-founder, CEO Calyxha Biotechnologies GmbH; Co-founder, president Eveliqure Biotechnologies GmbH; CEO, CSO Algonist Biotechnologies GmbH
Previously: Co-founder & CSO Arsanis, Inc (IPO, NASDAQ 2017, now X4 Pharma); SVP Research, Intercell AG (now Valneva SAS)
Mag. Wolfgang Friedl
Chief Operating Officer
CEBINA operations, facility, investor relations and legal
Attorney at Law, founder and senior partner of Vienna Legal Group; CEO MAG-LAB
Over 25 years experience in corporate law, national / international M&A, and financing with a strong focus on biotech
Sophie Zettl, PhD
Chief Business Officer
Business development, intellectual property, PR and communications
Over 15 years licensing / BD / IP experience in biotech, Pharma and University Technology Transfer Offices; CBO, COO Algonist Biotechnologies GmbH
Previously: Arsanis Inc, MedImmune / AstraZeneca, University College London, King’s College London
Gábor Nagy MD, PhD
VP Research & Technology Evaluation
14 years biotech R&D experience
Previously: Arsanis Inc, Eveliqure Biotechnologies GmbH (co-founder), Intercell AG (now Valneva SAS)
Valéria Szijártó, MD, PhD, MBA
VP Preclinical & Translational Research
10 years biotech R&D experience
Professional MBA in Entrepreneurship and Innovation at WU Executive Academy, Vienna
Previously: Arsanis Inc, Eveliqure Biotechnologies GmbH
Advisors and Investments
Patrick Aisher
Strategic investor / Investment advisor
Chairman of Kinled Holding, serial entrepreneur who has invested in the life science industry since 1997. Focus on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services, with direct investments in over 50 businesses, 24 exiting via IPO, trade sale or licensing.
Director of Aleva Neurotherapeutics SA, PreComb Therapeutics AG, has identified and invested in early-stage spin-off opportunities from Universities in Barcelona, Zurich, Oxford, Boston, Stanford, NorthEastern, Texas, NYU, Lausanne and Geneva.
Fabio Blom
Investment Committee Member